Sandbox Reserved 1170: Difference between revisions

@@ Line 27: / Line 27: @@
 == Clinical Relevance ==
-By signaling predominantly through G<sub>aq/11</sub>, GPR40 increases intracellular calcium and activates phospholipases to generate diacylglycerols resulting in increased insulin secretion. Synthetic small-molecule agonists of GPR40 enhance insulin secretion in a glucose dependent manner [http://www.merriam-webster.com/medical/in%20vitro in vitro] and [http://www.merriam-webster.com/medical/in%20vivo in vivo] with a mechanism similar to that found with fatty acids. GPR40 agonists have shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes.<ref name="Burant"/>
+By signaling predominantly through G<sub>aq/11</sub>, hGPR40 increases intracellular calcium and activates phospholipases to generate diacylglycerols resulting in increased insulin secretion. Synthetic small-molecule agonists of GPR40 enhance insulin secretion in a glucose dependent manner [http://www.merriam-webster.com/medical/in%20vitro in vitro] and [http://www.merriam-webster.com/medical/in%20vivo in vivo] with a mechanism similar to that found with fatty acids. GPR40 agonists have shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes.<ref name="Burant"/>
 === TAK-875 ===

Navigation menu